FOR IMMEDIATE DISTRIBUTION

Drug Advisory

Methyłfentanyl detected in Saskatchewan

- SASKATOON – January 22, 2024 - The Prescription Review Program (PRP) has been notified by Health Canada’s Drug Analysis Service that an Methyłfentanyl (N-(methylphenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide) was seized as a brown powder and/or grainy substance.

- Fentanyl was also detected as a co-occurring substance.

- The substance was received in the Health Canada Laboratory on December 11, 2023, and is the first detection of this substance of concern, in this form, in the Saskatoon area.

- The substance may also represent a threat to anyone handling it without taking the appropriate health and safety precautions.

- The Drug Analysis Service has instituted a policy to communicate advisories to clients as well as provincial and territorial public health authorities regarding potentially problematic substances. This policy aims to provide information, as part of an early warning system, to warn Canadians of new substances which may pose a potential health hazard.

The Prescription Review Program (PRP) is Saskatchewan’s prescription monitoring program. It monitors for potential inappropriate prescribing and inappropriate use of a provincially designated panel of monitored prescription drugs, as listed in Regulatory Bylaw 18.1, which have been deemed subject to misuse or abuse in the province.

Information: Prescription Review Program
prp@cps.sk.ca
Telephone: 1-306-244-7355 or 1-800-667-1668